FORMULATION DEVELOPMENT AND CHARACTERIZATION OF LYOPHILIZED FEBUXOSTAT NANOSUSPENSION

ANKITA HADKE; ANIL PETHE; SUNITA VAIDYA; SUNIL DEWANI

doi:10.22159/ijap.2022v14i6.45614

Authors

ANKITA HADKE Datta Meghe College of Pharmacy, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha, Maharashtra, India 442001 https://orcid.org/0000-0001-7163-0307
ANIL PETHE Datta Meghe College of Pharmacy, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha, Maharashtra, India 442001 https://orcid.org/0000-0002-6380-1847
SUNITA VAIDYA Datta Meghe College of Pharmacy, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha, Maharashtra, India 442001 https://orcid.org/0000-0003-4395-6048
SUNIL DEWANI Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha, Maharashtra, India 442001 https://orcid.org/0000-0002-5457-4937

DOI:

https://doi.org/10.22159/ijap.2022v14i6.45614

Keywords:

Febuxostat, Nanosuspension, PVP K-30, Sodium lauryl sulfate, Lyophilization

Abstract

Objective: The study aims to prepare and evaluate febuxostat nanosuspension to improve oral bioavailability.

Methods: Febuxostat nanosuspension was prepared by the solvent-antisolvent method, followed by a lyophilization technique using PVP K-30 as a stabilizer and sodium lauryl sulfate as a surfactant. Drug content, differential scanning calorimetry, powder x-ray diffraction, Fourier transform infrared spectroscopy, and in vitro dissolution studies were used to characterize the nanosuspension.

Results: The results of the characterization studies indicated the formation of nanosuspension. The lyophilized FXT NS particle size is 2170.2 nm, the PDI value is 0.63, the negative zeta potential is 1.6 mV, and the drug content is 19.02%. Functional characterization studies demonstrated that the particle size reduced due to the interaction between the stabilizer and surfactant.

Conclusion: It can be concluded that the prepared febuxostat nanosuspension enhances the aqueous solubility of FXT and improves its oral bioavailability.

Downloads

Download data is not yet available.

References

Pawar PG, Darekar AB, Saudagar RB. Formulation, development and evaluation of febuxostat loaded microsponges. IJRAT. 2019 May;7(5):523-33. doi: 10.32622/ijrat.752019326.

Dass R, Jaiswal S, Gupta G. Formulation and evaluation of febuxostat fast disintegrating tablet. Indo-Am J Pharm. 2014;4:2928-36.

Asif U, Sherwani AK, Akhtar N, Shoaib MH, Hanif M, Qadir MI. Formulation development and optimization of febuxostat tablets by direct compression method. Adv Polym Technol. 2016;35(2):129-35. doi: 10.1002/adv.21536.

Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1209-20. doi: 10.2147/tcrm.s3310. PMID 19337428, PMCID PMC2643102.

Tang J, Bao J, Shi X, Sheng X, Su W. Preparation, optimisation, and in vitro-in vivo evaluation of febuxostat ternary solid dispersion. J Microencapsul. 2018 Aug 18;35(5):454-66. doi: 10.1080/02652048.2018.1526339. PMID 30229692.

Yin YF, Guo Y, Song WD, Duan XC, Zheng XC, Zhong T. Improving solubility and oral bioavailability of febuxostat by polymer-coated nanomatrix. AAPS PharmSciTech. 2018;19(2):934-40. doi: 10.1208/s12249-017-0905-z. PMID 29079988.

Bhide P, D’cunha J, Fernandes N. Development and evaluation of febuxostat sublingual tablet formulation. Int J Pharmacol Res. 2018 Apr;10(2):1-8.

Sharma M, Parmar K, Baria A, Patel TM, Lalani R, Parikh RK. Gastro retentive tablet of febuxostat: formulation, drug release dynamics, and factorial design. World J Pharm Res. 2015;4(1):1063-84.

El-Shenawy AA, Abdelhafez WA, Ismail A, Kassem AA. Formulation and characterization of nanosized ethosomal formulations of antigout model drug (Febuxostat) prepared by cold method: in vitro/ex vivo and in vivo assessment. AAPS PharmSciTech. 2019;21(1):31. doi: 10.1208/s12249-019-1556-z. PMID 31858305.

Vimalson DC, Parimalakrishnan S, Jeganathan NS, Anbazhagan S. Solid dispersion technique to enhance the solubility and dissolution of febuxostat an bcs class II drug. Int J App Pharm. 2019;11(1):241-6. doi: 10.22159/ijap.2019v11i1.30539.

Reddy SM, Sundari TP. Formulation and evaluation of nanoemulsion for solubility enhancement of febuxostat. IJSDR. 2019 Jan;4(1):118-28.

Habib BA, Abd El-Samiae AS, El-Houssieny BM, Tag R. Formulation, characterization, optimization, and in vivo performance of febuxostat self-nano-emulsifying system loaded sublingual films. Drug Deliv. 2021;28(1):1321-33. doi: 10.1080/10717544.2021.1927247. PMID 34176376.

Geetha G, Poojitha U, Khan A. Various techniques for preparation of nanosuspension-a review. Int J Pharm Sci Rev Res. 2014 Sep;3(9):30-7.

Jadgav P, Yadav A. Formulation, optimization, and in vitro evaluation of polymeric nanosuspension of flurbiprofen. Asian J Pharm Clin Res. 2019;12(11):183-91.

Patel VR, Agrawal YK. Nanosuspensions: promising drug delivery systems. J Adv Pharm Technol Res. 2011 Apr;2(2):81-7. doi: 10.4103%2F2231-4040.82950, PMCID: PMC3217698, PMID: 22171298.

Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci. 2008;35(1-2):127-35. doi: 10.1016/j.ejps.2008.06.009. PMID 18644441.

Sutradhar KB, Khatun S, Luna IP. Increasing possibilities of nanosuspension. J Nanotechnol. 2013;2013:1-12. doi: 10.1155/2013/346581.

Kilor V, Sapkal N, Daud A, Humne S, Gupta T. Development of stable nanosuspension loaded oral films of glimepiride with improved bioavailability. Int J App Pharm. 2017;9(2):28-33. doi: 10.22159/ijap.2017v9i2.16714.

Aher SS, Malsane ST, Saudagar RB. Nanosuspension: an overview. Int J Curr Pharm Sci. 2017;9(3):9-23. doi: 10.22159/ijcpr.2017.v9i3.19584.

Degobert G, Aydin D. Lyophilization of nanocapsules: instability sources, formulation and process parameters. Pharmaceutics. 2021 Jul 21;13(8):34452072. doi: 10.3390/ pharmaceutics13081112, PMCID PMC8400524.

Ibrahim AH, Rosqvist E, Smatt JH, Ibrahim HM, Ismael HR, Afouna MI. Formulation and optimization of lyophilized nanosuspension tablets to improve the physicochemical properties and provide immediate release of silymarin. Int J Pharm. 2019;563:217-27. doi: 10.1016/ j.ijpharm.2019.03.064. PMID 30946894.

Telange DR, Denge R, Patil AT, Umekar MJ, Gupta SV, Dave VS. Pentaerythritol as an excipient/solid dispersion carrier for improved solubility and permeability of ursodeoxycholic acid. J Excp Food Chem. 2018 Sep;9(3):80-95.

Teymouri Rad RT, Mortazavi SA, Vatanara A, Dadashzadeh S. Enhanced dissolution rate of tadalafil nanoparticles prepared by sonoprecipitation technique: optimization and physicochemical investigation. Iran J Pharm Res. 2017;16(4):1335-48. PMID 29721025, PMCID PMC5843297.

Dhore PW, Dave VS, Saoji SD, Gupta D, Raut NA. Influence of carrier (polymer) type and drug-carrier-ratio in the development of amorphous dispersions for solubility and permeability enhancement of ritonavir. J Excipients Food Chem. 2017;8(3):1-18.

Al-Hamidi HA, Edwards AA, Mohammad MA, Nokhodchi A. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids Surf B Biointerfaces. 2010;76(1):170-8. doi: 10.1016/j.colsurfb.2009.10.030, PMID 19945828.

Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. Formulation, optimization and in vitro–in vivo evaluation of febuxostat nanosuspension. Int J Pharm. 2015;478(2):540-52. doi: 10.1016/j.ijpharm.2014.12.003. PMID 25490182.

Paswan SK, Saini TR. Comparative evaluation of in vitro drug release methods employed for nanoparticle drug release studies. Diss Technol. 2021 Nov;28(4):30-8. doi: 10.14227/DT280421P30.

Pongpeerapat A, Itoh K, Tozuka Y, Moribe K, Oguchi T, Yamamoto K. Formation and stability of drug nanoparticles obtained from drug/pvp/sds ternary ground mixture. J Drug Deliv Sci Technol. 2004;14(6):441-7. doi: 10.1016/S1773-2247(04)50082-5.

Ding Z, Wang L, Xing Y, Zhao Y, Wang Z, Han J. Enhanced oral bioavailability of celecoxib nanocrystalline solid dispersion based on wet media milling technique: formulation, optimization and in vitro/in vivo evaluation. Pharmaceutics. 2019;11(7). doi: 10.3390/pharmaceutics11070328. PMID 31336734.

Kuk DH, Ha ES, Ha DH, Sim WY, Lee SK, Jeong JS. Development of a resveratrol nanosuspension using the antisolvent precipitation method without solvent removal, based on a quality by design (QbD) approach. Pharmaceutics. 2019 Dec 17;11(12):1-22. doi: 10.3390/pharmaceutics11120688, PMID 31861173.

Ding Z, Wang L, Xing Y, Zhao Y, Wang Z, Han J. Enhanced oral bioavailability of celecoxib nanocrystalline solid dispersion based on wet media milling technique: formulation, optimization and in vitro/in vivo evaluation. Pharmaceutics. 2019;11(7):328. doi: 10.3390/pharmaceutics11070328, PMID 31336734.

Patel GV, Patel VB, Pathak A, Rajput SJ. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Drug Dev Ind Pharm. 2014;40(1):80-91. doi: 10.3109/ 03639045. 2012.746362, PMID 23323843.

Sundari PT, Lad K. Physico-chemical characterization and in vitro evaluation of febuxostat. Asian J Pharm. 2016 Apr;10(2):62-9.

Anjane M, Agrawal S, Khan A. Formulation and evaluation of nanosuspension of valsartan. Int J Curr Pharm Res. 2018;10(2):68-74.

Doppalapudi S, Suryadevara V, Jujala C. Formulation and evaluation of febuxostat fast dissolving tablets using entada scandens seed starch and poloxamer-188 as superdisintegrants. Int J App Pharm. 2019 Aug 6;11(5):241-50. doi: 10.22159/ijap.2019v11i5.34779.

Deshkar SS, Sonkamble KG, Mahore JG. Formulation and optimization of nanosuspension for improving solubility and dissolution of gemfibrozil. Asian J Pharm Clin Res. 2019;12(1):157-63. doi: 10.22159/ajpcr.2019.v12i1.26724.

Mohapatra PK, Sireesha, Rathore V, Verma HC, Rath BP, Sahoo S. Fabrication and in vitro characterization of a novel nanosuspension of telmisartan: a poorly soluble drug prepared by antisolvent precipitation technique using 33 factorial design. Int J Appl Pharm. 2020;12(5):286-94. doi: 10.22159/ijap.2020v12i5.38865.

Taani BL, Khanfar A, Alsuod OA. Enhancement of the release of curcumin by the freeze-drying technique using insulin and neusilin as carriers. Int J Appl Pharm. 2018;10(3):42-8. doi: 10.22159/ijap.2018v10i3.24429.